Actelion Pharmaceuticals Ltd
Actelion Pharmaceuticals Ltd., a leading biopharmaceutical company headquartered in Switzerland (CH), has established itself as a pioneer in the treatment of pulmonary arterial hypertension (PAH) and other serious conditions. Founded in 1997, Actelion has achieved significant milestones, including its acquisition by Johnson & Johnson in 2017, which further solidified its market position. The company focuses on innovative therapies, particularly in the areas of cardiovascular and infectious diseases, with a portfolio that includes unique products like Tracleer and Opsumit. These therapies are distinguished by their targeted mechanisms and proven efficacy, addressing unmet medical needs. Actelion's commitment to research and development has positioned it as a key player in the biopharmaceutical industry, recognised for its contributions to improving patient outcomes globally.
DitchCarbon Score
How does Actelion Pharmaceuticals Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Actelion Pharmaceuticals Ltd's score of 81 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Actelion Pharmaceuticals Ltd, headquartered in Switzerland (CH), currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Johnson & Johnson, and as such, it inherits emissions data and climate commitments from its parent organisation. Actelion's climate initiatives are aligned with those of Johnson & Johnson, which has set ambitious targets for reducing carbon emissions across its operations. These initiatives include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded from Johnson & Johnson. However, specific reduction targets or achievements for Actelion itself have not been disclosed. As a subsidiary, Actelion is expected to contribute to the overarching sustainability goals of Johnson & Johnson, which include significant reductions in Scope 1, 2, and 3 emissions. The company is committed to advancing climate action, although detailed metrics and specific targets for Actelion have not been provided.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Actelion Pharmaceuticals Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
